The p53-induced Siva-1 plays a significant role in cisplatin-mediated apoptosis by Barkinge, John L. et al.
Marshall University
Marshall Digital Scholar
Clinical & Translational Sciences School of Medicine
2-7-2009








See next page for additional authors
Follow this and additional works at: https://mds.marshall.edu/cts
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, and the
Oncology Commons
This Article is brought to you for free and open access by the School of Medicine at Marshall Digital Scholar. It has been accepted for inclusion in
Clinical & Translational Sciences by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu, beachgr@marshall.edu.
Recommended Citation
Barkinge JL, Gudi R, Sarah H, Chu F, Borthakur A, Prabhakar BS, Prasad KV. The p53-induced Siva-1 plays a significant role in
cisplatin-mediated apoptosis. J Carcinog 2009;8:2.
Authors
John L. Barkinge, Radhika Gudi, Hawkins Sarah, Fei Chu, Alip Borthakur, and Bellur S. Prabhakar
This article is available at Marshall Digital Scholar: https://mds.marshall.edu/cts/2
11
Journal of Carcinogenesis www.carcinogenesis.com
Journal of Carcinogenesis 
A peer reviewed journal in the fi eld of Carcinogenesis and Chemoprevention
Original Article
The p53 induced Siva-1 plays a signifi cant role in 
cisplatin-induced apoptosis
John L. Barkinge, Radhika Gudi, Hawkins Sarah, Fei Chu1, Alip Borthakur2, Bellur S. Prabhakar, 
Kanteti V. S. Prasad*
Department of Microbiology and Immunology, University of Illinois at Chicago, 835 S. Wolcott Ave., MC 790, Chicago, IL 60612 USA; 1Children’s Memorial Hospital, 
Northwestern University, Chicago, IL, 60614 USA; 2Department of Medicine, University of Illinois at Chicago, 60612 USA.
E-mail: kanteti@uic.edu   
*Corresponding author
Published: 7 February, 2009   Received: 11 November, 2008
Journal of Carcinogenesis 2009, 8:2 DOI:10.4103/1477-3163.45389 Accepted: 23 January, 2009
This article is available from: http://www.carcinogenesis.com/content/8/1/2
© 2009 Barkinge, 
Abstract
Background:  The pro-apoptotic protein Siva-1 functions in both extrinsic and intrinsic cell death signaling; 
however, the exact contribution of the endogenous Siva-1 to DNA damage-induced apoptosis is unclear. 
Using cisplatin, a chemotherapeutic drug, to induce DNA damage and cell death, we determined the role of 
Siva-1. Methods: Cisplatin treated HCT116 colorectal carcinoma cells (p53+/+ and -/-) were used in the 
study. With the help of recombinant lentivirus that can express siSiva (siRNA that specifi cally targets Siva-1), 
we also generated Siva-1 knockdown HCT116 cells. Apoptosis was determined by tetramethyl rhodamine 
methyl ester (TMRM) staining and propidium iodide (PI) staining. Results: Treatment with cisplatin induced 
Siva-1 expression in a p53 dependent manner. In Siva-1 knockdown p53+/+ HCT116 colorectal carcinoma 
cells, loss of Siva-1 expression conferred signifi cant resistance to cisplatin-induced apoptosis. Although Siva-1 
levels were positively regulated by p53, Siva-1-induced apoptosis did not require p53. Despite the fact that 
Siva-1 lacks even a minimal BH3 domain, similar to other proapoptotic Bcl2 family members induced by p53, 
we showed that Siva-1 mediated apoptosis is characterized by Bax oligomerization and cytochrome c leakage 
from mitochondria. The putative amphipathic helical region in Siva-1 (SAH) appeared to function analogously to 
a BH3 domain. Conclusion: The p53 induced Siva-1 is one of the effector molecules, which plays a signifi cant 
role in DNA damage-induced cell death. 
Keywords: Apoptosis, Bcl-2 family, cisplatin, cytochrome c, p53, Siva-1
Background
It is estimated that at least 50% of human cancers can be 
attributed to the ablation or dysfunction of the p53 gene.[1] As 
a transcription factor, p53 has been implicated in the regulation 
of numerous tumor suppressor genes. In cases of irreparable 
DNA damage, p53 is well-characterized by its ability to 
transcriptionally upregulate various Bcl-2 family target genes 
involved in apoptosis.[2] Studies have also identified genes outside 
the Bcl-2 family, which facilitate apoptosis and are regulated 
by p53.[3]. Among these, the Siva-1 gene is transcriptionally 
induced by p53, at levels exceeding that of Bax, in response to 
genotoxic stress.[4] Despite a growing understanding of the role 
of p53 in DNA damage response pathways, the exact function 
of many of its unique target genes remains to be elucidated.
Siva-1 signaling output influences both extrinsic and 
intrinsic apoptotic pathways.[5-10] DNA microarray analyses 
have demonstrated enhanced Siva-1 activity in response to 
chemotherapeutic agents in several transformed cell lines. [4,11- 12] 
Further, we have shown that Siva-1 can act synergistically with 
cisplatin and promote apoptosis in breast cancer cell lines, 
regardless of the p53 or Bcl-2 status.[13] This finding correlates 
with our previous observations of direct inhibition of Bcl-2 
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and Bcl-x
L
 by Siva-1, in response to genotoxic stress.[8-9] In 
the current study, we examined the role of Siva-1 in cisplatin-
mediated apoptosis in HCT116 p53 +/+ and p53-/-cells. 
Using siRNA to abrogate endogenous Siva-1 expression, we 
demonstrate the importance of its role in DNA damage-induced 
apoptosis in p53 WT cells. In addition, we show that expression 
of Siva-1 can promote apoptosis, even in cells devoid of p53 
function. Based on its ability to interact with Bcl-2 and Bcl-x
L
 
and to promote Bax oligomerization, we further propose that 
Siva-1 functions like a BH3- only pro-apoptotic member of 
the Bcl-2 family.     
Materials and Methods
Cell lines and Reagents
Colon cancer cells HCT116 p53+/+ and p53-/- (kind gifts 
of Dr. Bert Vogelstein, Johns Hopkins University,)) were 
cultured in McCoy’s 5A medium, supplemented with 10% 
FCS, 1 mM sodium pyruvate, 1 mM HEPES buffer, and 100 
U/mL antibiotic/antimycotic (Gibco, Invitrogen). Human T 
cell lymphoma Jurkat and MDA MB-231 human breast cancer 
cells were maintained with RPMI medium.
The chemotherapeutic reagent cisplatin was purchased from 
Sigma and prepared in dimethyl sulfoxide (DMSO); UV 
radiation doses were applied via an XL-1000 Spectrolinker 
(Spectronics Corp.) UV crosslinker. 
The following antibodies were purchased from companies that 
have been indicated; respective dilutions are also indicated 
for those used in western blotting analysis or intracellular 
staining: mouse monoclonal β actin (Sigma, 1:2,000); rabbit 
polyclonal caspase-9 (p-10) and Bax (Santa Cruz, 1:500); 
rabbit polyclonal Bcl-xL, Bcl-2, and green fluorescence protein 
(GFP) (Santa Cruz, 1:1,000); mouse monoclonal GST, Bax, 
Hemagglutinin (HA), and c-myc (Santa Cruz, 1:1,000); mouse 
monoclonalcytochrome C (BD Biosciences, 1:1,000); mouse 
monoclonal cytochrome C oxidase IV (COX IV) (Molecular 
Probes, Invitrogen, 1:1,000); Bax 6A7 (BD Biosciences); mouse 
monoclonal p53 (Cell Signaling Technologies, 1:1,000); rabbit 
IgG-HRP and mouse IgGHRP (Santa Cruz, 1:10,000); mouse 
IgG-HRP Trublot (Ebiosciences, 1:1,000); and mouse IgG-
FITC (Life Source Technologies, 1:200). The Siva-1 antibody 
was generated commercially in rabbits, via injection of a 
previously described recombinant Siva-1 protein, expressed in 
and isolated from BL21 E. coli strains[14]. Rabbit antiserum was 
further purified using Thiophilic Resin (Clontech, 1:1,000), 
supplemented as above (Gibco). 
Recombinant Lentiviruses
Generation of recombinant lentiviruses encoding either a 
scrambled control or unique shRNA sequences targeted 
against Siva-1 has been previously described.[10] HCT116 
p53+/+ and Jurkat cells were infected with equivalent titers 
of control and Siva-1 siRNA-producing viruses were applied 
to cells that were subsequently incubated for at least 48 hours 
prior to each experiment. The cells were further sorted on the 
basis of GFP expression (MoFlo High Speed Cell Sorter). The 
GFP expression after cell sorting was greater than 90%. The 
cell morphology and growth remained unchanged, indicating 
negligible cytotoxic effects (data not shown). Knockdown of 
endogenous Siva-1 was verified by western blotting with Siva-1 
antibody. Lentiviral stocks were propagated in 293T cells via 
calcium phosphate co-transfection of pNLSIN (Siva-1 siRNA 
or Scrambled siRNA), pcTAT, pcRev, and pHit/G plasmids. 
Transfections were performed in the evening and the cell 
culture media were changed the following morning; 24 hours 
later, the media containing viral stocks were collected, spun 
down at 4,000 RPM in a table-top centrifuge to clear cellular 
debris, and used directly for infection or stored at 20oC
Cell lysates and Inmmunoblotting
Preparation of whole cell lysates and various immunoblotting 
procedures were done according to previously published 
procedures.[10-12,15]
Apoptosis
The percentage of cells undergoing apoptosis was determined 
by propidium iodide analysis of apoptotic DNA (Sub-G1 peak), 
as well as tetramethylrhodamine ester (TMRM) staining of 
Jurkat cells, as has been described.[8-10] Apoptosis was quantified 
by flow cytometry, on the basis of high GFP expression (siRNA 
positive cells), low 7AAD staining and high TMRM patterns. 
TMRM negative cells fitting these parameters were considered 
apoptotic.
Subcellular Fractionation
This procedure was adapted from previously described 
protocols.[15-20] HCT116 p53-/- cells were harvested with 
corresponding media using cell scrapers and centrifuged at 200 
x g (4oC) for five minutes. The resulting pellet was washed with 
PBS (pH 7.4) and spun down, again under the same conditions. 
Cells were resuspended in hypotonic buffer (20 mM Hepes, pH 
7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM ethylene 
glycol tetraacetic acid (EGTA), protease inhibitor cocktail, 1X 
(Roche)) and incubated on ice for 10 minutes. They were lysed 
in a Dounce homogenizer by applying 50 strokes with a type 
B pestle. Hypotonic buffer containing 1M sucrose was added 
to the lysates, to obtain a final sucrose concentration of 250 
mM. Whole cell lysate samples from the suspension were set 
aside and the remaining volumes were centrifuged at 750 x g, 
to separate intact cells and nuclei. The resulting pellets were 
discarded and the supernatants were centrifuged further at 
10,000 x g for 10 minutes, to obtain heavy membrane (HM, 
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mitochondria-enriched) fractions. The supernatants were saved 
as the S-100/LM fractions and the HM fraction pellets lysed in 
NP40 buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1% NP40, 
v/v, 0.1% sodium deoxycholate) for western blotting analysis. 
MCF-7 mitochondria were prepared similarly, but disrupted 
by nitrogen cavitation.
Chemical Cross-linking
In order to observe Bax oligomers, MDA-MB-231 and HCT116 
cell lysates were prepared by fractionation and subsequently 
incubated with 10 mM bis-maleimide hexane (BMH, Pierce) 
or DMSO (vehicle control), in the dark for 30 minutes, at 
room temperature.[15] The reaction was quenched by adding 10 
mM β-mercaptoethanol. Samples were prepared for western 
blotting, as previously indicated and oligomerization was 
determined by molecular weight analysis.
Results 
Cisplatin-induced Siva-1 expression is p53 
dependent
To determine the significance of p53 expression on the pro-
apoptotic function of Siva-1, we took advantage of p53+/+ and 
p53-/- HCT116 cells in our studies. Cells of both genotypes 
were treated with cisplatin (100 µM) or DMSO for 16 hours 
and endogenous Siva-1 levels were analyzed by immunoblotting 
whole cell lysates with Siva-1 polyclonal antibody, as described 
previously.[14] While we observed a robust induction of Siva-1 
in response to cisplatin treatment in p53+/+ cells, we were 
unable to detect the protein in p53-/-cells (as compared to 
a relatively strong expression of beta-actin, used as a loading 
control) [Figure 1A]. To ensure that the cisplatin dose was 
sufficient to induce apoptosis, HCT116 cells were analyzed by 
propidium iodide staining. Significant levels of sub-G1 apoptotic 
DNA were observed in p53+/+ cells (increase from 2.14 to 
33.74%); conversely, as expected, p53-/- cells exhibited levels 
of apoptosis only slightly higher than that of control treated 
cells (4.03 to 9.47%) [Figure 1B]. 
In order to define the role of endogenous Siva-1 in DNA damage-
induced apoptosis and its relationship to p53, we generated 
Siva-1 knockdown p53+/+ HCT116 cells using Siva-1 
specific siRNA. The cells were transduced with recombinant 
lentiviruses encoding either unique Siva-1 siRNA (siSiva) or a 
corresponding scrambled control siRNA, as described by Gudi 
et al.[10] Since Siva-1 protein expression was not detectable in 
untreated cells [Figures 1A, 2A], we tested the effect of cisplatin 
treatment on apoptosis in siSiva and control cells. As shown 
in Figure 2A, cisplatin treatment induced significant Siva-1 
expression in HCT116 p53+/+ cells that were dramatically 
reduced by prior transduction with recombinant lentivirus, 
capable of expressing siSiva. 
Siva-1 plays an essential but partial role in DNA damage-
induced apoptosis.
We next treated both Siva-1 knockdown and control HCT116 
p53+/+ cells for 24 hours, with either cisplatin or DMSO. 
Apoptotic cells were quantified by flow cytometry using TMRM 
staining, to monitor loss of mitochondrial membrane potential. 
While control siRNA treated cells demonstrated a strong 
apoptotic response to cisplatin (about five-fold increase over 
mock treated cells), the percentage of programmed cell death in 
siSiva cells decreased by more than 50% and the difference was 
statistically significant at P<0.01 [Figure 2B]. To ensure that this 
effect was not cell type specific, Jurkat T cells were also similarly 
treated. As shown, a significantly diminished level of apoptosis 
was observed in siSiva cells treated with cisplatin [Figure 2C]. 
These findings clearly identify an essential but partial role for 
Figure 1: Cisplatin induces p53 dependent Siva-1 expression. 
HCT116 colon cancer p53+/+ and -/- cell lines (gift of Bert Vogelstein, 
Johns Hopkins University) were treated with DMSO (0, Control) 
or 100 µM cisplatin (CDDP, Sigma), incubated for 16 hours. (A) 
Endogenous Siva-1 expression by was determined SDS-PAGE and 
immunoblotting of lysates with Siva-1 polyclonal antibody. beta-
actin served as a loading control. (B) Apoptosis by propidium iodide 
staining. Percentages indicate sub-G1 apoptotic DNA analyzed by 
fl ow cytometry (FACScaliber, BD Biosciences)
A
B
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endogenous Siva-1 in cancer cell apoptosis engendered by 
cisplatin-induced terminal DNA damage. 
Siva-1 induces Bax oligomerization
In addition to its transcriptional role, p53 can function 
directly at the mitochondrial level and activate Bax, via a 
specific interaction with Bcl-x
L
.[15] In order to assess whether 
Siva-1 requires cytoplasmic p53 for its apoptotic function, 
we expressed Siva-1 in HCT116 p53-/- cells. Cells were 
transiently transfected with a GST-tagged Siva-1 or GST alone, 
incubated for 24 hours, and treated with cisplatin (100 µM) 
for a further 24 hours. Representative lysates were analyzed 
by immunoblotting for caspase-9 processing, a hallmark of 
activation of the intrinsic cell death pathway. As shown, a 
distinct caspas-9 related p17 cleavage product was visible in 
the lysates from Siva-1 expressing cells exposed to cisplatin; 
conversely, we were unable to detect this product in the case of 
cells expressing GST alone [Figure 2D, upper panel]. Although 
the relative expression of Siva-1 was considerably less than that 
of GST, it significantly enhanced cisplatin-induced apoptosis 
[Figure 2D, middle panel]. As expected, both the mutants 
migrated to a similar distance as that of the GST-Siva-1 WT on 
a 10% SDS-PAGE, since the difference in molecular weights 
was relatively small. We further determined that in contrast to 
Figure 2: Abrogation of Siva-1 expression signifi cantly impairs cisplatin-mediated apoptosis. (A) HCT116 p53+/+ or (C) Jurkat cells were 
transduced with lentiviruses encoding either Siva siRNA (siSiva) or scrambled control (Scr siRNA). Transduced cells were analyzed for 
Siva-1 expression (A). Percentage apoptosis in HCT116 p53+/+ (B) and Jurkat cells (C) are shown (D) HCT116 p53-/- cells were transfected 
with plasmids expressing GST, GST-Siva-1, GST-Siva-1∆SAH or GST-Siva-1∆C (residues 130-149) as described earlier.[8] The cell lysates 
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a corresponding control deletion mutant (∆C), a GST-Siva-1 
mutant, lacking the SAH region, was deficient in its ability to 
promote caspase-9 activation [Figure 2D, upper panel]. 
The Siva-1 SAH peptide can induce cytochrome c 
leakage in isolated mitochondrial fraction
Intrinsic apoptosis mediated by p53-induced apoptotic genes 
is characterized by the oligomerization of Bax and Bak whose 
function is normally curtailed by anti-apoptotic members 
such as Bcl-2 and Bcl-x
L
. Activated Bax oligomerizes and 
inserts into the mitochondrial membrane, thereby forming 
channels through which resident pro-apoptotic proteins 
such as cytochrome C leak into cytosol.[21] We made use of a 
chemical cross-linker (BMH) to observe such potential higher 
order Bax structures, as an indicator for intrinsic apoptosis. [22] 
MDA-MB-231 cells, known to lack functional p53, were 
transfected with either GST or GST-Siva-1 expressing plasmids; 
following a 24-hour expression period, cells were treated with 
suboptimal doses of cisplatin[13] or DMSO for 24-48 hours. 
Harvested lysates were then incubated with BMH, prior to 
immunoblotting, to covalently crosslink proteins. Intriguingly, 
in GST-Siva-1 expressing cells, Bax appeared to dimerize, even 
in the absence cisplatin treatment; following 24 and 48 hours 
of drug exposure, oligomeric complexes consistent with Bax 
trimers and tetramers, respectively, were observed, suggesting 
a clear progression in Bax activation over the experimental time 
period [Figure 3, upper right panel]. However, a vast majority 
of the Bax protein appeared to remain in a monomeric state 
in cells expressing GST, regardless of the duration of cisplatin 
treatment [Figure 3, upper left panel]. Expression levels of 
GST and GST-Siva-1 were determined and the specificity of 
the result upheld [Figure 3, lower panels]. 
Since proapoptotic BH3-only Bcl-2 family members function 
principally at the mitochondrial level, we next investigated 
the intracellular localization pattern of Siva-1. HCT116 
p53-/- cells were transduced with either Siva-1 or control 
IRES-GFP expressing recombinant adenoviruses; following 
24 hours of expression, cells were treated with cisplatin and 
subjected to hypotonic shock. They were then fractionated 
to obtain heavy membrane (mitochondria-enriched) isolates. 
Biochemical analysis of cells treated with cisplatin over a 4-8 
hour period revealed incremental accumulation of Siva-1 in the 
mitochondrial compartment [Figure 4A, upper right panel]. 
As observed previously, endogenous Siva-1 levels could not be 
detected in the p53-/- cell line [Figure 4A, upper left panel]. 
Whole cell lysate immunoblot analysis confirmed specific and 
appropriate viral transduction and Siva-1 expression [Figure 
4A, lower panels]. Having verified mitochondrial localization 
of Siva-1 in response to genotoxic stress and its independence 
of cytoplasmic p53, we further investigated the potential 
mechanistic consequences of Siva-1 at the mitochondrial level. 
We have previously demonstrated that sole expression of the 
SAH domain of Siva is sufficient to negate the protective effects 
of Bcl-x
L
 and Bcl-2 in response to DNA damage, resulting in 
cytochrome C release and consequent caspase-9 activation.[8-9,13] 
To investigate the functional relevance of current translocation 
data, isolated heavy membrane fractions from MCF-7 cells 
stably expressing GFP or a GFP-tagged version of Bcl-x
L
 
were incubated with either 5 [Figure 4B: SAH1, CTL1] or 10 
(SAH2, CTL2) µg of synthetic peptides, corresponding to the 
SAH region of Siva-1 (amino acid residues 36-55) or a control 
downstream region (amino acid residues 130-149). Equivalent 
mitochondria (pellet) and corresponding supernatant fractions 
were then assessed for cytochrome C by western blot. As 
shown, mitochondria from GFP expressing cells exhibited 
nearly complete efflux of cytochrome C from pellet fractions, 
when treated with either concentration of SAH peptide; this 
corresponded with reciprocal accumulation in the supernatant. 
Mitochondria treated with either concentration of control 
peptide demonstrated comparatively less cytochrome C release 
[Figure 4B, left panels]. Interestingly, a similar effect was 
observed when mitochondria from cells stably expressing GFP-
Bcl-x
L
 were treated with SAH peptide. Notably, however, higher 
peptide concentrations were required for significantly enhanced 
cytochrome C efflux. This is likely due to enhanced levels of 
expression of Bcl-x
L 
in transfected cells, which necessitated 
higher quantities of SAH peptide to overcome the protective 
effect of Bcl-x
L.
 Mitochondria treated with control peptide 
Figure 3: Siva-1 promotes Bax activation in response to cisplatin 
treatment. MDA-MB-231 cells transiently expressing GST or 
GST-Siva-1 were treated with DMSO or cisplatin (50 µM) for the 
indicated time points (upper panels). Cells were iterated with BMH 
cross-linker (Pierce) to observe Bax multimers; arrows indicate 
monomeric, dimeric, and oligomeric forms (upper panels). In a 
parallel experiment, appropriate expression levels and protein 
loading were confi rmed using GST and and # β; actin antibodies, 
respectively (lower panels)
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elicited little or no effect [Figure 4A, right panels]. This suggests 
that the SAH region of Siva is both necessary and sufficient to 
evoke cytochrome C release from mitochondria, reminiscent 
of a BH3 domain-like mechanism, and it supports previous and 
current data demonstrating SAH dependent intrinsic apoptotic 
initiation via caspase-9 [Figure 2D].
Discussion
In this paper, we have shown that Siva-1, a pro-apoptotic protein 
that lacks a true BH3 domain, behaves like a small BH3 only 
protein and plays a significant and essential but partial role in 
genotoxic (p53-induced) apoptosis. Using the colorectal cancer 
cell line HCT116, we have clearly shown the dependence of 
Siva-1 intracellular expression on functional p53. The expressed 
Siva-1 targets mitochondria and induces Bax oligomerization 
and caspase-9 activation and the twenty amino acid putative 
helical region in Siva-1 (SAH) is the principal mediator. 
Our data demonstrating the dependence of endogenous 
Siva-1 expression on induced p53 activity is in accordance 
with previous reports published by Pommmier and coworker 
(2003) using gene profiling. They showed that the topoisomerase 
inhibitor topotecan induces Siva-1 expression (transcripts) in 
a p53 dependent manner.[12] A previous study of differential 
gene expression analysis using cell cycle and apoptosis DNA 
microarray in cisplatin treated Hep3B cells also reveals 
significant induction of Siva expression.[11] In addition, our data 
is also in agreement with a report previously published by Slack 
and coworkers that p53 as well as E2F1 directly activate the 
transcription of Siva-1.[4] It is therefore not surprising that p53, 
a powerful tumor suppressor, induces apoptosis in susceptible 
cells by upregulating transcription of the pro-apoptotic gene 
Siva-1. As shown in Figure 2A, Siva-1 knockdown alone appears 
to promote cell survival; however, we have observed this only 
in HCT116 but not in Jurkat cells and, therefore, disregarded 
the observation. The maximum effect of Siva-1, however, was 
seen in cells treated with various apoptotic stimuli.[7-10,13]
Although it lacks significant homology to the Bcl-2 family 
per se, we have shown here that the ability of Siva-1 to bind 
anti-apoptotic proteins like Bcl-x
L
 may consequently result 
in direct activation of Bax and cytochrome C release. The 
unique putative twenty amino acid SAH region in Siva-1 was 
shown by us to be essential for its apoptotic function. Based 
on our earlier observation,[10] it appears to behave like the 
Figure 4: Siva-1 and cytochrome C release. (A) HCT116 p53-/- cells 
were infected with either Siva-1 (Adeno-Siva-1) or GFP (Adeno-
GFP) and treated as shown. Heavy membrane fraction lysates 
were analyzed for Siva-1 and COX IV expression (upper panels); 
corresponding whole cell lysate samples were analyzed for Siva-1 
and GFP expression levels (lower panel). (B) Heavy membrane 
fractions (30 µg) from MCF-7 cells stably expressing either GFP 
or GFP-Bcl-xL[8] were incubated with either 5 or 10 µg of SAH or 
control peptides. At 30 minutes, the fractions were analyzed for 
cytochrome C
Figure 5: Siva-1 plays a necessary but partial role in genotoxic-
induced apoptosis; p53 is a central player in DNA damage-induced 
apoptosis and it triggers transcription of several pro-apoptotic 
genes such as Siva-1, Puma, Noxa, Bax etc. Siva-1, though principally 
regulated by p53 transcriptional activity, can function independent 
of p53 (unlike Puma), whereas Noxa appears to be important for 
mediation of ROS-induced cell death. Finally, the apoptosis pathways 
are kept in check by cell survival pathways, wherein Siva-1 is known 
to inhibit NF-kappa B.[10]
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BH3 only peptide of Bid, in inducing apoptosis.[16] The time 
dependent increase in expressed Siva-1 in heavy membrane 
fraction, upon cisplatin treatment, is highly likely to be due 
its localization to mitochondria, Here we have shown that 
treatment of mitochondrial fraction with the above peptide 
results in cytochrome C leakage; in our previous studies, we 
demonstrated that it can specifically interact with Bcl2 or Bcl-
xl but not Bax.[13] Thus, induction of Siva-1 by p53 (genotoxic 
stress) is likely to result in its translocation to mitochondria 
and neutralize the pro-survival effects of Bcl2 anti-apoptotic 
members. This explains the enhanced Bax oligomerization seen 
in cells forced to overexpress Siva-1 [Figure 3]. 
A large body of work supports the idea that the antiapoptotic 
members such as Bcl2 and Bcl-xL counteract the apoptotic 
effects of Bax and Bak and thus act as sentinels of cell survival. 
Under conditions where the DNA is damaged and irreparable 
(genotoxic stress), the relatively small proapoptotic molecules 
such as Bid, Bad and Puma interfere with the above interaction, 
resulting in the release of Bax and Bak and their oligomerization. 
Oligomerization of Bax and Bak, in turn, results in loss in 
mitochondrial integrity and leakage of cytochrome c. The 
above events are typically induced by small BH3 only apoptotic 
molecules that are induced by p53. Siva-1, although induced 
by p53, is not a member of the Bcl2 family and yet induces 
oligomerization of Bax. 
P53 is known to induce intrinsic apoptosis in a transcriptional 
independent as well as transcriptional dependent manner. 
The most well characterized proapoptotic proteins that are 
transcriptionally regulated by p53 are Bax and the BH3 only 
protein Puma.[17] In normal cell, the levels of p53 are very 
low; however, they are rapidly elevated upon induction of 
DNA damage. This results in accumulation of p53 in cytosol. 
The apoptotic activity of p53 is neutralized by Bcl2 and Bcl-
xl. Under the above conditions, Puma levels are also known 
to increase. It has a high affinity for Bcl2 and Bcl-xL and, 
thus, displaces p53 from Bcl2 and Bcl-xl, resulting in intrinsic 
apoptosis.[18] There appears to be a strong dependence of Puma 
for p53, since it fails to induce significant apoptosis in p53 null 
cells.[2,18] In this sense, Siva-1 appears to be different from that of 
Puma. Its ability to promote intrinsic cell death does not require 
p53, since expression of Siva-1 in p53 null cells also enhances 
cisplatin-induced cell death [Figure 2D].[13] Since elimination 
of DNA damaged cells to prevent tumorigenesis is a very 
important function, it appears to be regulated by redundant 
and overlapping pathways. For instance, p53 regulated Noxa 
appears to have a definitive role in ROS-induced cell death, 
whereas Puma is an essential mediator of DNA damage-induced 
cell death. The role of Puma appears to be somewhat limited by 
functional p53, although its transcription can also be regulated 
by E2F1. 
Recently, an essential role for Siva-1 was also shown in 
campotheticin-induced apoptosis in cerebellar neuronal 
granules, that was also p53 dependent.[23] The fact that 
expression of Siva-1 can potentiate cisplatin-induced apoptosis 
even in the absence of a functional p53 means that Siva-1 is 
likely to play a role in genotoxic stress-induced apoptosis, even 
if p53 is mutated and non-functional, as is the case with almost 
50% of cancers. 
Although we have shown that Siva-1 plays an essential and 
significant role in cisplatin-induced intrinsic cell death, despite 
the knockdown of Siva-1 expression, the cells still undergo 
considerable apoptosis. This could be explained by the fact that 
p53 induces transcription of several apoptotic genes, other 
than Siva-1, and these could be responsible for the residual 
cell death.[17]
Conclusions
We have attempted to depict the complex regulation of DNA 
damage-induced apoptosis in the model shown in Figure 5. 
There is no doubt that p53 is a central player recruited by 
the cell, in response to DNA damage, and it decides the fate 
of the cell mainly by switching on specific gene transcription 
programs. By itself and by positively increasing the transcription 
of several apoptotic genes, it triggers intrinsic cell death. Siva-1 
is one of the effectors of p53; however, its transcription can 
also be triggered by other transcription factors such as E2F1. 
Unlike Puma, Siva-1 mediates cell death in a p53 independent 
manner. The fact that Siva-1 can also potentially inhibit NF-
kappa B activation that promotes transcription of several cell 
survival molecules[10] also makes Shiva-1 a unique effector of 
p53 mediated apoptosis.
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